| Drug Name | GPCR-targeted Project 007 |
| Description |
A bispecific antibody that simultaneously targets two cancer stem cell receptors (LGR5 and LGR4) is in early preclinical development for the treatment of solid tumors. |
| Target | Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4); Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) |
| Drug Modality | Bispecific antibody |
| Indication | Solid tumors |
| Product Category | Biologic |
| Mechanism of Action | G protein-coupled receptor antagonists |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |